RhumbLine Advisers’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-67,157
| Closed | -$2.31M | – | 3070 |
|
|
2020
Q3 | $2.31M | Sell |
67,157
-22,170
| -25% | -$472K | ﹤0.01% | 1595 |
|
|
2020
Q2 | $1.49M | Buy |
89,327
+11,653
| +15% | +$198K | ﹤0.01% | 1876 |
|
|
2020
Q1 | $1.12M | Buy |
77,674
+8,843
| +13% | +$226K | ﹤0.01% | 1830 |
|
|
2019
Q4 | $2.3M | Buy |
68,831
+4,941
| +8% | +$138K | ﹤0.01% | 1721 |
|
|
2019
Q3 | $1.34M | Buy |
63,890
+462
| +0.7% | +$9.43K | ﹤0.01% | 1907 |
|
|
2019
Q2 | $1.32M | Buy |
63,428
+5,975
| +10% | +$123K | ﹤0.01% | 1939 |
|
|
2019
Q1 | $1.28M | Sell |
57,453
-494
| -0.9% | -$11.6K | ﹤0.01% | 1917 |
|
|
2018
Q4 | $1.39M | Buy |
57,947
+18,916
| +48% | +$489K | ﹤0.01% | 1855 |
|
|
2018
Q3 | $1.06M | Sell |
39,031
-2,700
| -6% | -$76.4K | ﹤0.01% | 1981 |
|
|
2018
Q2 | $1.12M | Buy |
41,731
+8,348
| +25% | +$255K | ﹤0.01% | 1956 |
|
|
2018
Q1 | $1.06M | Sell |
33,383
-480
| -1% | -$16.9K | ﹤0.01% | 1915 |
|
|
2017
Q4 | $1.28M | Sell |
33,863
-6,287
| -16% | -$203K | ﹤0.01% | 1841 |
|
|
2017
Q3 | $995K | Buy |
40,150
+590
| +1% | +$12.7K | ﹤0.01% | 1981 |
|
|
2017
Q2 | $813K | Buy |
39,560
+9,928
| +34% | +$189K | ﹤0.01% | 2054 |
|
|
2017
Q1 | $644K | Buy |
29,632
+995
| +3% | +$20.4K | ﹤0.01% | 2148 |
|
|
2016
Q4 | $586K | Buy |
28,637
+3,030
| +12% | +$61.9K | ﹤0.01% | 2137 |
|
|
2016
Q3 | $384K | Buy |
25,607
+4,407
| +21% | +$59.5K | ﹤0.01% | 2357 |
|
|
2016
Q2 | $229K | Buy |
21,200
+10,520
| +99% | +$143K | ﹤0.01% | 2670 |
|
|
2016
Q1 | $145K | Buy |
+10,680
| New | +$167K | ﹤0.01% | 2827 |
|
RhumbLine Advisers's AIMT Position: Q4 2020 in Review
RhumbLine Advisers sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 67,157 shares — an estimated $2.31M sold.
RhumbLine Advisers first reported a position in AIMT in Q1 2016 and held it in 19 quarters. The position peaked at $2.31M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- RhumbLine Advisers reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- RhumbLine Advisers sold 67,157 Aimmune Therapeutics shares in Q4 2020, an estimated $2.31M.
- RhumbLine Advisers first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 19 quarters.
- RhumbLine Advisers's Aimmune Therapeutics position peaked at $2.31M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on RhumbLine Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.